New CDC Study Finds That Greater Than 20% Of American Adults Suffer From Chronic Pain With Opioid Addiction A Key Factor; The Chronic Pain Market, Accelerated By COVID-19 Pandemic, Seen Reaching $151.7 Billion By 2030 With Treatments By Medical Firms

A new research study by The Centers For Disease Control And Prevention (CDC) finds that greater than 20% of American adults suffer from chronic pain and high-impact chronic pain, sometimes resulting in opioid dependence. The COVID-19 pandemic, a recent study by Prescient & Strategic Intelligence reports, only exacerbates these numbers and will help drive the chronic pain treatment market globally by a 6.5% CAGR rate to $151.7 Billion by 2030 from $77.8 Billion in 2019. Medical firms such as Electromedical Technologies, Inc. (OTCQB: EMED) offer alternative treatments. EMED also collaborates with Universities and Schools on researching the chronic pain market and treatments.

The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).

New CDC Study Finds That Greater Than 20% Of American Adults Suffer From Chronic Pain With Opioid Addiction A Key Factor; The Chronic Pain Market, Accelerated By COVID-19 Pandemic, Seen Reaching $151.7 Billion By 2030 With Treatments By Medical Firms Such As Electromedical Technologies, Inc. (OTCQB: EMED)

The new CDC study finds that chronic pain and high-impact chronic pain that 20.4% of American adults have chronic pain that only grows worse with age -- rates of pain were highest among adults aged 65 or older. The incidence of chronic pain was reported higher for women than men. Incidences were higher in rural than urban areas, the research found. New CDC Study Finds That Greater Than 20% Of American Adults Suffer From Chronic Pain With Opioid Addiction A Key Factor; The Chronic Pain Market, Accelerated By COVID-19 Pandemic, Seen Reaching $151.7 Billion By 2030 With Treatments By Medical Firms Such As Electromedical Technologies, Inc. (OTCQB: EMED).

Electromedical Technologies, Inc. (OTCQB: EMED) At The Forefront Of Future Medicine

Electromedical Technologies, Inc. (OTCQB: EMED) is a leader in this field of addressing acute and chronic pain and sees itself at the forefront of future medicine. Opioid addiction from pain-killer pharmaceuticals, is only made worse by COVID-19. The global pandemic causes patients with chronic pain to limit or avoid physical visits, postpone surgical treatments and limit out-of-home mobility. New CDC Study Finds That Greater Than 20% Of American Adults Suffer From Chronic Pain With Opioid Addiction A Key Factor; The Chronic Pain Market, Accelerated By COVID-19 Pandemic, Seen Reaching $151.7 Billion By 2030 With Treatments By Medical Firms Such As Electromedical Technologies, Inc. (OTCQB: EMED).

Coming In The Future: The Wearable Wellness Pro(R) Pod

Electromedical Technologies, Inc. (OTCQB: EMED) offers a growing line of FDA-cleared WellnessPro Plus(TM) devices that deliver electrotherapy treatment for chronic and acute pain. Next year, the Company anticipates bringing to market its WellnessPro(R) Pod. The Company is collaborating with numerous universities and schools to research the field of bioelectronics. It is seeking to develop a program to study the effects of electro-modulation on the human body, especially cell signaling and virus assembly and immune responses. New CDC Study Finds That Greater Than 20% Of American Adults Suffer From Chronic Pain With Opioid Addiction A Key Factor; The Chronic Pain Market, Accelerated By COVID-19 Pandemic, Seen Reaching $151.7 Billion By 2030 With Treatments By Medical Firms Such As Electromedical Technologies, Inc. (OTCQB: EMED).

The WellnessPro Plus(TM) is a non-invasive device designed to avoid painkiller pharmaceuticals and opioid addiction

The COVID-19 pandemic has been long-lasting and been the source of various anxiety and stress disorders, causing more severe pain to patients and presenting an effort to develop pain-fighting devices such as those marketed by Electromedical Technologies, Inc. (OTCQB: EMED).A commercial stage company, Electromedical Technologies, Inc. (OTCQB: EMED) is planning to launch another device in 2021, the WellnessPro(R) Pod. It is collaborating with universities and colleges to establish a comprehensive research program that defines the effects of electro-modulation on the human body.

Chronic Pain Treatment Market Projected To Reach $151.7 Billion By 2030

Research firm Prescient & Strategic Intelligence sees the chronic pain treatment market hitting $151.7 Billion by 2030, reflecting a CAGR of 6.5%% during the forecast period from 2020-2030. The pandemic accelerated the opioid epidemic crisis in the research period. The report finds that North America dominates the global chronic pain market.

Electromedical Technologies, Inc. (OTCQB: EMED) Collaborating With Universities And Schools To Research The Field And Establish Certification And Training Programs

EMED is seeking to also collaborating with more universities and colleges to certify therapists in this field to relationships with universities and schools and raise the profile of bioelectronics and its available non-opioid treatments. Electromedical Technologies, Inc. (OTCQB: EMED) announced recently that it had reached agreement to collaborate with the Energetic Wellness School of Naturopathy to develop a new distribution platform and certification training program for "Bioelectronics Therapist and Master Device Technician." The certification program and curriculum are pending approval, the School said.

A 'Hands On' Understanding Of The Benefits Of Electrotherapy Treatment

Matthew Wolfson, founder and CEO of Electromedical Technologies, Inc. (OTCQB: EMED), said, "Doctors and students will have access to the Wellness Pro(R) Plus devices, which will give them a hands-on understanding of the various techniques and benefits of using drug free application techniques for chronic, acute post traumatic and intractable pain."

Source: Stock Market Press

Join Stock Market Press' newsletter for the latest in IPO, market commentary and company profiles.

Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.

Contact:

Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:

Statements in this news release may be "forward-looking statements." Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

See Stock Market Press disclaimer: http://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press

comtex tracking

COMTEX_374167699/2718/2020-11-09T08:51:42

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.